Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …

Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Background Multidrug resistance (MDR) mediated by ATP binding cassette subfamily B
member 1 (ABCB1/P-gp) is a major cause of cancer chemotherapy failure, but the regulation …

Colorectal cancer (CRC), which shows a high degree of heterogeneity, is the third most
deadly cancer worldwide. Mutational activation of KRASG12D occurs in approximately 10 …

Despite significant progress in clinical management, drug resistance remains a major
obstacle. Recent research based on protein degradation to restrain drug resistance has …

Igf2bp1 is an oncofetal RNA binding protein whose expression in numerous types of
cancers is associated with upregulation of key pro-oncogenic RNAs, poor prognosis, and …

KRAS mutations are the drivers of various cancers, including non–small cell lung cancer,
colon cancer, and pancreatic cancer. Over the last 30 years, immense efforts have been …

The strategic fluorination of oxidatively vulnerable sites in bioactive compounds is a
relatively recent, widely used approach allowing us to modulate the stability, bio-absorption …

Chemotherapy is one of the important methods to treat cancer, and the emergence of
multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy …